Literature DB >> 11090153

Expression of an altered ribonucleotide reductase activity associated with the replication of murine cytomegalovirus in quiescent fibroblasts.

D Lembo1, G Gribaudo, A Hofer, L Riera, M Cornaglia, A Mondo, A Angeretti, M Gariglio, L Thelander, S Landolfo.   

Abstract

Ribonucleotide reductase (RNR) is an essential enzyme for the de novo synthesis of both cellular and viral DNA and catalyzes the conversion of ribonucleoside diphosphates into the corresponding deoxyribonucleoside diphosphates. The enzyme consists of two nonidentical subunits, termed R1 and R2, whose expression is very low in resting cells and maximal in S-phase cells. Here we show that murine cytomegalovirus (MCMV) replication depends on ribonucleotide reduction since it is prevented by the RNR inhibitor hydroxyurea. MCMV infection of quiescent fibroblasts markedly induces both mRNA and protein corresponding to the cellular R2 subunit, whereas expression of the cellular R1 subunit does not appear to be up-regulated. The increase in R2 gene expression is due to an increase in gene transcription, since the activity of a reporter gene driven by the mouse R2 promoter is induced following virus infection. Cotransfection experiments revealed that expression of the viral immediate-early 1 protein was sufficient to mediate the increase in R2 promoter activity. It was found that the viral gene M45, encoding a putative homologue of the R1 subunit, is expressed 24 and 48 h after infection. Meanwhile, we observed an expansion of the deoxyribonucleoside triphosphate pool between 24 and 48 h after infection; however, neither CDP reduction nor viral replication was inhibited by treatment with 10 mM thymidine. These findings indicate the induction of an RNR activity with an altered allosteric regulation compared to the mouse RNR following MCMV infection and suggest that the virus R1 homologue may complex with the induced cellular R2 protein to reconstitute a new RNR activity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11090153      PMCID: PMC112436          DOI: 10.1128/jvi.74.24.11557-11565.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  61 in total

1.  A procedure to standardize CAT reporter gene assay.

Authors:  H Abken; B Reifenrath
Journal:  Nucleic Acids Res       Date:  1992-07-11       Impact factor: 16.971

2.  Controlled protein degradation regulates ribonucleotide reductase activity in proliferating mammalian cells during the normal cell cycle and in response to DNA damage and replication blocks.

Authors:  A Chabes; L Thelander
Journal:  J Biol Chem       Date:  2000-06-09       Impact factor: 5.157

3.  Human cytomegalovirus stimulates cellular dihydrofolate reductase activity in quiescent cells.

Authors:  D Lembo; G Gribaudo; R Cavallo; L Riera; A Angeretti; L Hertel; S Landolfo
Journal:  Intervirology       Date:  1999       Impact factor: 1.763

4.  Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds.

Authors:  R Pauwels; J Balzarini; M Baba; R Snoeck; D Schols; P Herdewijn; J Desmyter; E De Clercq
Journal:  J Virol Methods       Date:  1988-08       Impact factor: 2.014

5.  The human cytomegalovirus IE1-72 protein interacts with the cellular p107 protein and relieves p107-mediated transcriptional repression of an E2F-responsive promoter.

Authors:  E E Poma; T F Kowalik; L Zhu; J H Sinclair; E S Huang
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

6.  Overexpression of a hexa-histidine and T7 peptide-tagged human ribonucleotide reductase small subunit, R2 in Escherichia coli and the generation of human R2 antibodies.

Authors:  M Kuo; T Kinsella
Journal:  Int J Oncol       Date:  1997-03       Impact factor: 5.650

7.  Human cytomegalovirus inhibits cellular DNA synthesis and arrests productively infected cells in late G1.

Authors:  W A Bresnahan; I Boldogh; E A Thompson; T Albrecht
Journal:  Virology       Date:  1996-10-01       Impact factor: 3.616

8.  Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant.

Authors:  D J Goldstein; S K Weller
Journal:  Virology       Date:  1988-09       Impact factor: 3.616

9.  Human cytomegalovirus infection inhibits cell cycle progression at multiple points, including the transition from G1 to S.

Authors:  M Lu; T Shenk
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

10.  CCAAT box-dependent activation of the TATA-less human DNA polymerase alpha promoter by the human cytomegalovirus 72-kilodalton major immediate-early protein.

Authors:  G P Hayhurst; L A Bryant; R C Caswell; S M Walker; J H Sinclair
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

View more
  19 in total

1.  Optimization and evaluation of electroporation delivery of siRNA in the human leukemic CEM cell line.

Authors:  Anna Fyrberg; Kourosh Lotfi
Journal:  Cytotechnology       Date:  2010-10-19       Impact factor: 2.058

2.  Cell cycle arrest by human cytomegalovirus 86-kDa IE2 protein resembles premature senescence.

Authors:  Emanuela Noris; Claudia Zannetti; Anna Demurtas; John Sinclair; Marco De Andrea; Marisa Gariglio; Santo Landolfo
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

Review 3.  Viral latency drives 'memory inflation': a unifying hypothesis linking two hallmarks of cytomegalovirus infection.

Authors:  Christof K Seckert; Marion Griessl; Julia K Büttner; Sabine Scheller; Christian O Simon; Kai A Kropp; Angélique Renzaho; Birgit Kühnapfel; Natascha K A Grzimek; Matthias J Reddehase
Journal:  Med Microbiol Immunol       Date:  2012-09-19       Impact factor: 3.402

4.  Reevaluation of the coding potential and proteomic analysis of the BAC-derived rhesus cytomegalovirus strain 68-1.

Authors:  Daniel Malouli; Ernesto S Nakayasu; Kasinath Viswanathan; David G Camp; W L William Chang; Peter A Barry; Richard D Smith; Klaus Früh
Journal:  J Virol       Date:  2012-06-20       Impact factor: 5.103

5.  CD8 T cells control cytomegalovirus latency by epitope-specific sensing of transcriptional reactivation.

Authors:  Christian O Simon; Rafaela Holtappels; Hanna-Mari Tervo; Verena Böhm; Torsten Däubner; Silke A Oehrlein-Karpi; Birgit Kühnapfel; Angélique Renzaho; Dennis Strand; Jürgen Podlech; Matthias J Reddehase; Natascha K A Grzimek
Journal:  J Virol       Date:  2006-08-23       Impact factor: 5.103

6.  Effect of the human cytomegalovirus IE86 protein on expression of E2F-responsive genes: a DNA microarray analysis.

Authors:  Yoon-Jae Song; Mark F Stinski
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-26       Impact factor: 11.205

7.  Vaccinia virus-encoded ribonucleotide reductase subunits are differentially required for replication and pathogenesis.

Authors:  Don B Gammon; Branawan Gowrishankar; Sophie Duraffour; Graciela Andrei; Chris Upton; David H Evans
Journal:  PLoS Pathog       Date:  2010-07-08       Impact factor: 6.823

8.  Murine cytomegalovirus major immediate-early enhancer region operating as a genetic switch in bidirectional gene pair transcription.

Authors:  Christian O Simon; Birgit Kühnapfel; Matthias J Reddehase; Natascha K A Grzimek
Journal:  J Virol       Date:  2007-05-09       Impact factor: 5.103

9.  Transactivation of cellular genes involved in nucleotide metabolism by the regulatory IE1 protein of murine cytomegalovirus is not critical for viral replicative fitness in quiescent cells and host tissues.

Authors:  Vanessa Wilhelmi; Christian O Simon; Jürgen Podlech; Verena Böhm; Torsten Däubner; Simone Emde; Dennis Strand; Angélique Renzaho; Niels A W Lemmermann; Christof K Seckert; Matthias J Reddehase; Natascha K A Grzimek
Journal:  J Virol       Date:  2008-08-06       Impact factor: 5.103

10.  Ribonucleotide reductase inhibitors hydroxyurea, didox, and trimidox inhibit human cytomegalovirus replication in vitro and synergize with ganciclovir.

Authors:  Sukhada Bhave; Howard Elford; Michael A McVoy
Journal:  Antiviral Res       Date:  2013-08-06       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.